The Filing Desk

Aspen Aerogels

ASPN · NYSE · Materials · Financials, fiscal 2016 to 2025

ASPN · Last close · November 13, 2026
$5.58
Value Aspen Aerogels yourself

Aspen Aerogels' revenue fell 40.1% to $271 million in fiscal 2025. Its operating margin was −139.5%, down from 12.1% a year earlier. Free cash flow was −$5 million. The diluted share count rose 2.5%.

ASPEN AEROGELS INC Latest fiscal year ended December 31, 2025 10-K filed March 13, 2026 · 0001193125-26-106453 Updated
Revenue
$271M
40.1%
Operating margin
−139.5%
151.6 pts
Net income
−$390M
$13M a year earlier
Free cash flow
−$5M
 
Return on capital
−93.7%
103.8 pts
Market cap
$464M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Net debt to EBITDA for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Aspen Aerogels does

Aspen Aerogels makes aerogel, a very light insulating material. It sells two main kinds of products: thermal barriers that sit between battery cells in electric vehicles and energy storage systems to slow the spread of a battery fire, and insulation blankets for refineries, chemical plants, liquefied natural gas facilities and power plants.

The electric vehicle market and the energy industrial insulation market are its two principal markets. It has production contracts with General Motors, which can end them at any time, and with Toyota, Scania, Audi, Volvo Truck and others. General Motors was 59% of total revenue in 2025. Its insulation is sold through distributors, contractors and manufacturers of equipment. It says its products cost more than traditional insulation.

Aspen Aerogels competes with makers of other aerogel products, such as Armacell and Alkegen, and with traditional insulation makers. It had 854 full-time employees at the end of 2025.

Its biggest risks, as it describes them

  • Depending on General Motors for most of its revenue, with a contract General Motors can end at any time.
  • Its electric vehicle business depends on carmakers' plans and on consumers buying electric vehicles.
  • Relying on outside factories in China to supply part of its aerogel.
  • Needing more money for growth and keeping to the terms of its credit agreement.
  • Competition from other aerogel and traditional insulation makers, and high prices for its products.
From Aspen Aerogels's annual report on Form 10-K, filed March 13, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Aspen Aerogels lost money in fiscal 2025: a net loss of $390 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments77281140221157
Debt incl. finance leases—1041159570
Net debt (negative means net cash)—−178−25−126−86
Net debt to EBITDA———−1.6x—
Debt to equity—0.2x0.2x0.1x0.3x
Interest coverage−172.0x−517.9x−49,203.0x7.8x−30.9x
Current ratio3.1x4.7x3.4x3.7x3.9x
Quick ratio2.7x4.4x2.9x3.3x3.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Aspen Aerogels' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Aspen Aerogels says to expect

  • Fourth quarter 2026: revenueQ4 2026 Revenue is expected to range between $60 million and $75 million
  • Fourth quarter 2026: net lossQ4 2026 Net loss is expected to range between $11 million and $8 million
  • Fourth quarter 2026: adjusted EBITDAQ4 2026 Adjusted EBITDA is expected to range between $5 million and $13 million, which excludes an estimated $5 million to $10 million of East Providence incident-related costs, including expedited freight and expedited repair costs, professional fees, and the incremental cost of temporarily sourcing certain products from the Company's external manufacturing facility until the East Providence facility returns to full production capacity; the Company is engaged in the claims process under its insurance policies with respect to these costs
  • Full year 2026: capital expendituresFY 2026 Capital Expenditures, excluding costs related to the restoration of the East Providence facility, are expected to be less than $10 million
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Aspen Aerogels shares on the open market, and 1 insider sold $58.1 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 23, 2026Wood River Capital LLCFormer 10% OwnerSold12,280,426$4.73$58.1 millionForm 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 98 of 94 of 9
Rule of 40−59.0%80.6%−41.8%
Altman Z''0.552.50−10.32
Accruals ratio−0.5%−4.0%−64.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassFail
Cash from operations is positiveFailPassPass
Return on assets rosePassPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassPass
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin rosePassPassFail
Revenue rose relative to assetsFailPassFail
F-score4 of 98 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Aspen Aerogels side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Aspen AerogelsFY25−40.1%−139.5%−1.7%−93.7%—4
Core Molding TechnologiesFY25−9.4%5.2%0.7%8.2%−0.8x6Compare
Perimeter SolutionsFY2516.4%−30.8%31.9%−10.2%—5Compare
EcovystFY2520.9%9.0%9.7%2.9%1.4x6Compare
Alto IngredientsFY25−4.9%0.8%0.9%2.5%1.9x6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue118112104139100122180239453271
Revenue growth−3.9%−5.2%−6.5%33.5%−28.1%21.3%48.3%32.4%89.6%−40.1%
Gross profit23191326151055718346
Research and development566891117161813
Operating income−11−19−34−14−22−41−79−4954−378
Net income−12−19−34−15−22−37−83−4613−390
Diluted EPS (US$)−0.52−0.83−1.45−0.60−0.83−1.22−2.10−0.660.17−4.73
Diluted shares (millions)23232424263039698082
Cash flow
Cash from operations−1−5−9−1−10−19−94−434633
Capital expenditure136423141781768637
Free cash flow−14−11−12−3−13−32−272−218−41−5
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation554455911139
Balance sheet at fiscal year end
Cash and short-term investments1811341677281140221157
Debt incl. finance leases————4—1041159570
Total assets1351249910497183643703895407
Total liabilities192329443054196215280171
Shareholders' equity116101705968128447488615236
Margins and ratios
Gross margin19.8%16.7%12.1%18.9%14.6%8.2%2.8%23.8%40.4%17.0%
Operating margin−9.5%−17.1%−32.5%−10.2%−21.5%−33.4%−43.9%−20.6%12.1%−139.5%
Net margin−10.2%−17.3%−33.0%−10.4%−21.8%−30.5%−45.9%−19.2%3.0%−143.7%
Free cash flow margin−11.7%−9.6%−11.7%−2.3%−13.3%−26.6%−151.0%−91.3%−9.0%−1.7%
Rule of 40 (growth + FCF margin)−15.6%−14.8%−18.2%31.3%−41.4%−5.3%−102.7%−59.0%80.6%−41.8%
Return on capital———————−10.6%10.2%−93.7%
Return on equity−10.1%−17.9%−40.2%−22.5%−34.4%−37.8%−28.7%−9.8%2.4%−91.6%
Return on assets−8.8%−14.9%−30.9%−14.4%−21.7%−26.5%−20.0%−6.8%1.7%−59.9%
Net debt to EBITDA————————−1.6x—
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Aspen Aerogels' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Aspen Aerogels.